Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbadis.2013.01.008PMID 23314196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular

  2019cited by this paper
• Incretins

  2015cited by this paper
• Diabetes

  2013cited by this paper
• Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.

  2013cited by this paper
• Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

  2013cited by this paper
• Incretin-based therapies

  2012cited by this paper
• A Randomized Controlled Trial of a Tailored Primary Care Program to Reverse Excessive Alcohol Consumption

  2012cited by this paper
• Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance

  2012cited by this paper
• Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

  2012cited by this paper
• Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis

  2012influential reference
• Insulin in Central Nervous System: More than Just a Peripheral Hormone

  2012influential reference
• Glucagon‐Like Peptide‐1 Regulation of Carbohydrate Intake Is Differentially Affected by Obesogenic Diets

  2012cited by this paper
• Alzheimer's Disease and Diabetes: An Integrative View of the Role of Mitochondria, Oxidative Stress, and Insulin

  2012cited by this paper
• Metabolic Alterations Induced by Sucrose Intake and Alzheimer’s Disease Promote Similar Brain Mitochondrial Abnormalities

  2012influential reference
• Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4

  2012influential reference
• Impairment of GLP1‐induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia

  2012cited by this paper
• Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.

  2012cited by this paper
• Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation.

  2012cited by this paper
• Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.

  2012cited by this paper
• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

  2012cited by this paper
• Lixisenatide for type 2 diabetes mellitus

  2011cited by this paper
• Impact of STZ‐induced hyperglycemia and insulin‐induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters

  2011influential reference
• Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Is the GLP-1 system a viable therapeutic target for weight reduction?

  2011influential reference
• Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

  2011cited by this paper
• Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

  2011influential reference
• Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus

  2011cited by this paper
• Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

  2011cited by this paper
• Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

  2011cited by this paper
• Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4.

  2011cited by this paper
• Neuroprotective properties of GLP-1: theoretical and practical applications

  2011cited by this paper
• Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.

  2011cited by this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus Current and Emerging Agents

  2011cited by this paper
• Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation.

  2011cited by this paper
• The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.

  2011cited by this paper
• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

  2010cited by this paper
• Exendin‐4 protects pancreatic beta cells from human islet amyloid polypeptide‐induced cell damage: potential involvement of AKT and mitochondria biogenesis

  2010cited by this paper
• Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes.

  2010cited by this paper
• Mitochondrial Amyloid-β Levels are Associated with the Extent of Mitochondrial Dysfunction in Different Brain Regions and the Degree of Cognitive Impairment in Alzheimer's Transgenic Mice

  2010cited by this paper
• Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides

  2010influential reference
• The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.

  2010cited by this paper
• The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease.

  2010cited by this paper
• Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia.

  2010cited by this paper
• GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

  2010influential reference
• Pharmacological Characterization of Human Incretin Receptor Missense Variants

  2010cited by this paper
• Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

  2010cited by this paper
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance

  2010cited by this paper
• RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

  2010cited by this paper
• Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

  2010cited by this paper
• Exenatide and weight loss.

  2010influential reference
• Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.

  2010cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.

  2010cited by this paper
• The role of GLP-1 in neuronal activity and neurodegeneration.

  2010cited by this paper
• Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes.

  2010cited by this paper
• Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement.

  2010cited by this paper
• Mitochondrial stress and the pathogenesis of diabetic neuropathy

  2010cited by this paper
• Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes.

  2010cited by this paper
• Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

  2010cited by this paper
• GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.

  2010cited by this paper
• Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.

  2010cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• How does diabetes accelerate Alzheimer disease pathology?

  2010influential reference
• Diabetes regulates mitochondrial biogenesis and fission in mouse neurons

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus.

  2009cited by this paper
• Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease

  2009cited by this paper
• Insulin and the brain

  2009cited by this paper
• Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia

  2009cited by this paper
• Phosphorylation of IRS proteins, insulin action, and insulin resistance.

  2009cited by this paper
• (Pre)diabetes, brain aging, and cognition.

  2009cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus

  2009influential reference
• Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

  2009cited by this paper
• Proteólisis cerebral del péptido amiloide-ß: Relevancia de la enzima degradadora de insulina en la enfermedad de Alzheimer

  2009cited by this paper
• The incretin system and its role in type 2 diabetes mellitus.

  2009cited by this paper
• Brain inflammation and adult neurogenesis: the dual role of microglia.

  2009cited by this paper
• GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

  2009influential reference
• Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

  2009cited by this paper
• The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Protein and glutamine kinetics during counter-regulatory failure in type 1 diabetes.

  2009cited by this paper
• Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

  2009cited by this paper
• Impaired neurogenesis in adult type-2 diabetic rats.

  2009influential reference
• Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease

  2009cited by this paper
• One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

  2009cited by this paper
• Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity

  2009cited by this paper
• Incretin-Based Therapies

  2009cited by this paper
• Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.

  2009cited by this paper
• An Integrative View of the Role of Oxidative Stress, Mitochondria and Insulin in Alzheimer's Disease

  2009influential reference
• Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.

  2009cited by this paper
• Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.

  2009cited by this paper
• [Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].

  2009cited by this paper
• An Integrated and Unifying Hypothesis for the Metabolic Basis of Sporadic Alzheimer's Disease

  2008cited by this paper
• Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin

  2008cited by this paper
• Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

  2008cited by this paper

• Relationship between Alzheimer's Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms.

  2025cites this paper
• Relationship Between Depression and Decreased Activity Level and Cognitive Impairment in Patients with Diabetes Mellitus Type 2 and/or Atrial Fibrillation

  2025cites this paper
• Nano-conjugation of small molecule modulators of protein aggregation: Enhancing the therapeutic precision.

  2025cites this paper
• Applying the Causal Roadmap to longitudinal national registry data in Denmark: A case study of second-line diabetes medication and dementia

  2025cites this paper
• Neuropathological links between T2DM and LOAD: systematic review and meta-analysis.

  2025cites this paper
• Prevalence and Predictors of Cognitive Decline Among Diabetes Mellitus Patients Attending Jinja Regional Referral Hospital: A Cross‐Sectional Study in Eastern Uganda

  2025cites this paper
• Cognitive Dysfunction and Dementia in Type 2 Diabetes Mellitus: Insights into Mechanisms, Models, and Therapeutics.

  2025cites this paper
• Obesity-induced Neuronal Senescence: Unraveling the Pathophysiological Links.

  2024cites this paper
• Glycosphingolipids Associated Metabolic Disorders

  2024cites this paper
• A Systematic Review of Semaglutide’s Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies

  2024cites this paper
• Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients: A Real-World Cross-Sectional Study in Mysuru, India

  2023cites this paper
• The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease

  2023cites this paper
• Brain insulin resistance linked Alzheimer’s and Parkinson’s disease pathology: An undying implication of epigenetic and autophagy modulation

  2023cites this paper
• Resveratrol and Gut Microbiota Synergy: Preventive and Therapeutic Effects

  2023cites this paper
• Sphingolipid metabolism in brain insulin resistance and neurological diseases

  2023cites this paper
• Applying the causal roadmap to longitudinal national Danish registry data: a case study of second-line diabetes medication and dementia

  2023cites this paper
• Targeting mitochondrial dysfunction to salvage cellular senescence for managing neurodegeneration.

  2023cites this paper
• Dementia in Diabetes: The Role of Hypoglycemia

  2023cites this paper
• Effects of GLP-1 receptor agonists on neurological complications of diabetes

  2023cites this paper
• Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.

  2022cites this paper
• The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

  2022cites this paper
• Omarigliptin Mitigates 6-Hydroxydopamine- or Rotenone-Induced Oxidative Toxicity in PC12 Cells by Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Actions

  2022cites this paper
• Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases

  2022influential citation
• Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson’s disease when considering the coexisting effects of diabetes mellitus

  2022cites this paper
• Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies.

  2022cites this paper
• Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease

  2022cites this paper
• Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome

  2022cites this paper
• Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease: Review and Meta-Analysis

  2022cites this paper
• Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells

  2022cites this paper
• Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus.

  2022cites this paper
• Mitochondrial Dysfunction and Mitophagy Closely Cooperate in Neurological Deficits Associated with Alzheimer’s Disease and Type 2 Diabetes

  2021cites this paper
• Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS

  2021cites this paper
• Glucose signaling in the brain and periphery to memory.

  2020cites this paper
• Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota

  2020cites this paper
• Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway

  2020cites this paper
• Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function

  2020cites this paper
• Antidepressant activity of anti-hyperglycemic agents in experimental models: A review.

  2020cites this paper
• Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy.

  2020cites this paper
• Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

  2020cites this paper
• The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence

  2020cites this paper
• Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice

  2020cites this paper
• Do Nutrition Habits Influence the Clinical Presentation of Parkinson’s Disease?1

  2020cites this paper
• Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases

  2019cites this paper
• Re-thinking the Etiological Framework of Neurodegeneration

  2019cites this paper
• Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O.

  2019cites this paper
• Rotenon ile İndüklenen İn Vitro Parkinson Hastalığı Modelinde Glukagon Benzeri Peptid-1 Analoğu Ekzenatidin Nöron Sağkalımına Etkisi

  2019cites this paper
• Incretins today: multiple effects and therapeutic potential

  2019cites this paper
• Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: A retrospective cohort study

  2019cites this paper
• Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes

  2019cites this paper
• Effects of GLP-1 Receptor Activation on a Pentylenetetrazole—Kindling Rat Model

  2019cites this paper
• The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases

  2019cites this paper
• Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer’s disease and type 2 diabetes

  2019cites this paper
• Expression of insulin and GLP-1 receptors in interneurons of the cerebral cortex

  2019cites this paper
• Clinical aspects and prospects of using DPP-4 inhibitors

  2019cites this paper
• Title: Biochemical linkage of type 2 diabetes mellitus and Alzheimer’s disease

  2019cites this paper
• Specifics of diabetes in old age

  2019cites this paper
• Neurometabolic Evidence Supporting the Hypothesis of Increased Incidence of Type 3 Diabetes Mellitus in the 21st Century

  2019cites this paper
• Specifics of diabetes in old age

  2019cites this paper
• Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

  2018cites this paper
• Glucagon‐like peptide‐1 mediates effects of oral galactose in streptozotocin‐induced rat model of sporadic Alzheimer's disease

  2018influential citation
• Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats

  2018cites this paper
• Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease

  2018cites this paper
• Restoration of Rostral Ventrolateral Medulla Cystathionine-γ Lyase Activity Underlies Moxonidine-Evoked Neuroprotection and Sympathoinhibition in Diabetic Rats

  2018cites this paper
• Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis.

  2018cites this paper
• Low glucagon-like peptide-1 (GLP-1) concentration in serum is indicative of mild cognitive impairment in type 2 diabetes patients.

  2018cites this paper
• Irisin Exerts Neuroprotective Effects on Cultured Neurons by Regulating Astrocytes

  2018cites this paper
• Insulin Resistance in Alzheimer's Disease

  2018cites this paper
• The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity

  2018cites this paper
• The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction

  2018cites this paper
• Electrical Excitability of the Endoplasmic Reticulum Membrane Drives Electrical Bursting and the Pulsatile Secretion of Insulin in a Pancreatic Beta Cell Model

  2018cites this paper
• The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells

  2018cites this paper
• EFFECTIVENESS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN STREPTOZOTOCIN INDUCED NEURODEGENERATIVE MICE

  2018cites this paper
• Akutni učinak galaktoze na oksidativni stres i metabolizam u moždanom deblu štakorskog modela sporadične Alzheimerove bolesti

  2018cites this paper
• Diabetes mellitus a poruchy kognice z pohledu diabetologa

  2018cites this paper
• The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease.

  2017cites this paper
• Risk Factors for Alzheimer’s Disease

  2017cites this paper
• Synthesis and anti-diabetic activity of new N,N-dimethylphenylenediamine-derivatized nitrilotriacetic acid vanadyl complexes.

  2017cites this paper
• Novel GLP‐1R/GIPR co‐agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

  2017cites this paper
• Management of diabetes in older adults.

  2017cites this paper
• Role of Diet and Nutritional Supplements in Parkinson's Disease Progression

  2017cites this paper
• Unpuzzling the Comorbid Type 2 Diabetes and Hypertension-Related Cognitive Dysfunction and Stroke

  2017cites this paper
• The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders

  2017cites this paper
• EVALUATION OF ANXIOLYTIC AND ANTIDEPRESSANT ACTIVITY OF SITAGLIPTIN AND LINAGLIPTIN IN RATS

  2017cites this paper
• Effects of stevia on synaptic plasticity and NADPH oxidase level of CNS in conditions of metabolic disorders caused by fructose

  2017cites this paper
• Glucagon‐like Peptide‐1 (GLP‐1) and neurotransmitters signaling in epilepsy: An insight review

  2017cites this paper
• Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.

  2017cites this paper
• The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics

  2017cites this paper
• Diabetes, neurodegenerative diseases, GLP-1 & surgery: evidence calls for exploration

  2017cites this paper
• Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

  2017cites this paper
• Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

  2017cites this paper
• Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole‐induced acute epileptogenesis in mice: Implication of oxidative, inflammatory, apoptotic and autophagy pathways

  2017cites this paper
• A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis

  2017cites this paper
• HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

  2017cites this paper
• Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and in vivo

  2017cites this paper
• Nutrition in Parkinson’s disease

  2017cites this paper
• Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology

  2016cites this paper
• Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice

  2016cites this paper
• ZiBu PiYin recipe prevents diabetes-associated cognitive decline in rats: possible involvement of ameliorating mitochondrial dysfunction, insulin resistance pathway and histopathological changes

  2016cites this paper
• GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator

  2016cites this paper
• Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon‐like peptide‐1 receptor agonist, exendin‐4

  2016cites this paper